Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).

PET prostate cancer prostate-specific membrane antigen radiation therapy randomized clinical trial

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
25 Apr 2024
Historique:
received: 03 11 2023
revised: 28 03 2024
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 25 4 2024
Statut: aheadofprint

Résumé

This multicenter randomized phase III trial (NCT04457245) evaluated the effect of performing prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy.

Identifiants

DOI: 10.2967/jnumed.123.267004 PMID: 38664019
pubmed: 38664019
pii: jnumed.123.267004
doi: 10.2967/jnumed.123.267004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

John Nikitas (J)

Department of Radiation Oncology, UCLA, Los Angeles, California.

Ethan Lam (E)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Kiara Adame Booker (KA)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Wolfgang P Fendler (WP)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Matthias Eiber (M)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Boris Hadaschik (B)

Department of Urology, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Ken Herrmann (K)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Nader Hirmas (N)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Helena Lanzafame (H)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium-University Hospital Essen, Essen, Germany.

Martin Stuschke (M)

Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and.

Johannes Czernin (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Michael L Steinberg (ML)

Department of Radiation Oncology, UCLA, Los Angeles, California.

Nicholas G Nickols (NG)

Department of Radiation Oncology, UCLA, Los Angeles, California.
Radiation Oncology Service, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California.

Amar U Kishan (AU)

Department of Radiation Oncology, UCLA, Los Angeles, California.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California; jcalais@mednet.ucla.edu.

Classifications MeSH